Real-World Study of Treat-to-Target Strategy and Disease Management in Adults with Crohns Disease and Ulcerative Colitis

What this Trial Is About

Inflammatory Bowel Disease IBD, including Crohns Disease and Ulcerative Colitis, is a chronic condition causing inflammation in the digestive tract. This observational study is designed to evaluate how a treat-to-target T2T strategy is being applied worldwide in real-life settings for adults with IBD, and how this approach relates to disease outcomes over a 24-month period. The study collects data retrospectively and focuses on IBD as a whole, as well as separately for Crohns Disease and Ulcerative Colitis. Participants in this study will not receive any new treatments as part of the trial but will continue their usual care as managed by their healthcare providers. The study involves reviewing medical records from the past 24 months using electronic case report forms to gather relevant information about treatment approaches and disease progression. No additional visits or interventions are required from the participants. During the study, researchers will analyze the percentage of participants managed using the T2T strategy within 12 weeks and examine how this relates to disease outcomes. Since this is a retrospective chart review, there are no extra procedures or visits, and no additional burden for participants. The study will follow participants existing medical records for a total of 24 months from the inclusion date.

A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting